Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

Bossymc May. 20 at 10:47 PM

$QNCX some great additional news. 🤞🏼 Orphai Therapeutics presented positive Phase 2a clinical data for its investigational inhaled rapamycin therapy, LAM-001, at the American Thoracic Society (ATS) International Conference. The results and the subsequent corporate acquisition by Quince Therapeutics are detailed in the GlobeNewswire Press Release.Clinical Data HighlightsDrug Candidate: LAM-001 (a proprietary, inhaled formulation of sirolimus/rapamycin) evaluated as an add-on therapy. Target Conditions: Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Key Findings: At 24 weeks, the Phase 2a trial demonstrated clinically meaningful improvements in lung function, including a 67.4-meter increase in the 6-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR)

0 · Reply

Bossymc May. 20 at 9:37 PM

$QNCX I think we should hear something tomorrow about the closing of the 115 million financing. Hopefully it brings some volume. 😊😉🙏🏽

0 · Reply

Cmash1 May. 20 at 7:47 PM

$QNCX I’m in

0 · Reply

nys5 May. 20 at 5:05 PM

$QNCX

0 · Reply

CheckingMorons May. 20 at 3:00 PM

$QNCX HCWB 4k profit pump and index huge green and here it is QNCX doing nothing

0 · Reply

Bossymc May. 20 at 1:41 PM

$QNCX 😉

0 · Reply

nys5 May. 20 at 10:02 AM

$QNCX let’s see how this will play today

0 · Reply

WUXIANLONG May. 19 at 7:47 PM

$QNCX 121k sell wall wtf!!

2 · Reply

_BUBBLES_ May. 19 at 5:39 PM

$QNCX This is moving real similar to how it did before the R/S.. .085-.125 levels same as .90-1.20.. key support was .08 I could be wrong obviously, and this isn’t advice.. just an opinion of someone who’s been playing this since February.. we could press $2 again before eow.. GLTA🫡

2 · Reply

Swihart_Art May. 19 at 5:14 PM

$QNCX step 1: learn to spell step 2: spend over 10 years trading...

1 · Reply

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026, 10:00 AM EDT - 2 days ago

Quince Therapeutics Transcript: Investor update

May 18, 2026, 10:00 AM EDT - 2 days ago

Quince Therapeutics Press release: Investor update

May 18, 2026, 10:00 AM EDT - 2 days ago

Quince Therapeutics Slides: Investor update

2026-05-18T13:41:04.000Z - 2 days ago

Quince Therapeutics announces LAM-001 data

2026-05-18T13:35:06.000Z - 2 days ago

Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed

May 18, 2026, 9:26 AM EDT - 2 days ago

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026, 9:26 AM EDT - 2 days ago

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 17, 2026, 7:00 AM EDT - 3 days ago

Quince Therapeutics Slides: Presentation

May 11, 2026, 7:00 AM EDT - 9 days ago

Quince Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 23 days ago

Quince Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 23 days ago

Quince Therapeutics Proxy statement: Proxy filing

2026-04-21T12:49:06.000Z - 4 weeks ago

Largest borrow rate increases among liquid names

BHP CHPT PCT SPIR YPF

Apr 17, 2026, 8:00 AM EDT - 4 weeks ago

Quince Therapeutics Proxy statement: Proxy filing

2026-04-16T14:15:30.000Z - 4 weeks ago

Largest borrow rate increases among liquid names

ALTO INDA MRLN RUM VWAV WRD

2026-04-10T23:53:15.000Z - 5 weeks ago

Quince Therapeutics trading halted, news pending

2026-04-10T12:45:57.000Z - 5 weeks ago

Largest borrow rate increases among liquid names

BBD BBDO BKLN BYND CBRL CGC MSTX

Apr 10, 2026, 7:00 AM EDT - 5 weeks ago

Quince Therapeutics Annual report: Q4 2025

2026-03-30T12:54:26.000Z - 7 weeks ago

Quince Therapeutics settles $16.4M of debt

Mar 30, 2026, 8:30 AM EDT - 7 weeks ago

Quince Therapeutics Settles Approximately $16.4 Million of Debt

2026-03-23T17:35:47.000Z - 2 months ago

Quince Therapeutics options imply 68.7% move in share price post-earnings

2026-02-10T12:58:18.000Z - 3 months ago

Why Is Quince Therapeutics Stock (QNCX) Up Today?

Feb 9, 2026, 4:05 PM EST - 3 months ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 29, 2026, 3:10 PM EST - 3 months ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 4 months ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Dec 15, 2025, 8:00 AM EST - 5 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 5 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Dec 3, 2025, 10:30 AM EST - 6 months ago

Quince Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 6 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 13, 2025, 7:00 AM EST - 6 months ago

Quince Therapeutics Slides: Investor Presentation

Nov 12, 2025, 4:05 PM EST - 6 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:00 PM EST - 6 months ago

Quince Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 6 months ago

Quince Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:05 PM EST - 6 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 10:00 AM EDT - 8 months ago

Quince Therapeutics Transcript: Investor Day 2025

Oct 2, 2025, 10:00 AM EDT - 8 months ago

Quince Therapeutics Slides: FY 2025

Sep 25, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Quince Therapeutics Slides: Investor Presentation

Sep 11, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Quince Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Quince Therapeutics Slides: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Quince Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Quince Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 25, 2025, 8:00 AM EDT - 10 months ago

Quince Therapeutics Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 11 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 7:00 AM EDT - 11 months ago

Quince Therapeutics Slides: Investor Presentation

Jun 18, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 1 year ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Earnings release: Q1 2025

May 7, 2025, 3:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Earnings release: Q4 2024

Mar 24, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Annual report: Q4 2024

Feb 12, 2025, 2:00 PM EST - 1 year ago

Quince Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Transcript: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Press release: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Slides: Investor Update

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 5, 2025, 6:00 PM EST - 1 year ago

Quince Therapeutics Slides: Investor Presentation

Dec 18, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 6:00 PM EST - 1 year ago

Quince Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 6:00 PM EST - 1 year ago

Quince Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Transcript: The ThinkEquity Conference 2024

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Slides: FY 2024

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: LD Micro Main Event XVII

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Slides: LD Micro Main Event XVII

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 6:00 PM EDT - 1 year ago

Quince Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 6:00 PM EDT - 1 year ago

Quince Therapeutics Earnings release: Q2 2024

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Slides: The Citizens JMP Life Sciences Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Quarterly report: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q1 2024

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Mar 31, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Annual report: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q4 2023

Mar 26, 2024, 4:00 PM EDT - 2 years ago

Quince Therapeutics Transcript: Study Update

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 7, 2024, 4:30 PM EST - 2 years ago

Quince Therapeutics Transcript: 7th Annual Neuroscience Innovation Forum

Jan 7, 2024, 4:30 PM EST - 2 years ago

Quince Therapeutics Slides: 7th Annual Neuroscience Innovation Forum

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

Bossymc May. 20 at 10:47 PM

0 · Reply

Bossymc May. 20 at 9:37 PM

$QNCX I think we should hear something tomorrow about the closing of the 115 million financing. Hopefully it brings some volume. 😊😉🙏🏽

0 · Reply

Cmash1 May. 20 at 7:47 PM

$QNCX I’m in

0 · Reply

nys5 May. 20 at 5:05 PM

$QNCX

0 · Reply

CheckingMorons May. 20 at 3:00 PM

$QNCX HCWB 4k profit pump and index huge green and here it is QNCX doing nothing

0 · Reply

Bossymc May. 20 at 1:41 PM

$QNCX 😉

0 · Reply

nys5 May. 20 at 10:02 AM

$QNCX let’s see how this will play today

0 · Reply

WUXIANLONG May. 19 at 7:47 PM

$QNCX 121k sell wall wtf!!

2 · Reply

_BUBBLES_ May. 19 at 5:39 PM

2 · Reply

Swihart_Art May. 19 at 5:14 PM

$QNCX step 1: learn to spell step 2: spend over 10 years trading...

1 · Reply

FBabehh May. 19 at 5:00 PM

$QNCX this guy ehh... before he was talking bout that nobody knew shit... youre just a fake ass pumper! This stock is trash people and this guy is youre example!!

1 · Reply

Swihart_Art May. 19 at 4:15 PM

$QNCX The biggest thing is probably this: QNCX now has a plausible pathway to becoming a legitimate development-stage biotech again instead of a dying shell. That is a very meaningful transformation. And honestly, I think that’s why buyers are still showing up around the $1 area despite the dilution math scaring people initially.

1 · Reply

WUXIANLONG May. 19 at 4:09 PM

$QNCX holee shyt. So close to panic selling during premarket low 0.9s. Thanks to bulls here i stayed in 🙌🙌🙌

1 · Reply

Swihart_Art May. 19 at 4:00 PM

$QNCX yep... up nicely on a .98 entry, riding to at least 1.20...

0 · Reply

Joshuastride May. 19 at 3:59 PM

$QNCX stocks tend to do the opposite of what everyone expects..

0 · Reply

Papluch May. 19 at 3:28 PM

$QNCX This specifically says: “Oversubscribed $115M upfront financing” That matters a lot. It means: demand exceeded the amount being raised, more investors wanted in than allocation available. That is NOT what distressed biotech financings usually look like. Distressed raises usually: struggle to fill, use toxic convertibles, involve predatory lenders. This looks much more like: a strategic institutional biotech syndicate. 💪🚀🚀🚀🚀🚀.

0 · Reply

Papluch May. 19 at 3:20 PM

$QNCX This financing syndicate is honestly the strongest part of the entire QNCX story right now. In biotech, who funds a company matters almost as much as the science itself. The market watches elite healthcare funds because they: perform extremely deep due diligence, often get access to management/data rooms, specialize in evaluating clinical probabilities, typically avoid weak/dead biotech structures. So when multiple respected biotech funds pile into the same deal, institutions notice. The bullish institutional thesis is likely: “The merged company could eventually be worth substantially more than current enterprise value, and this financing bridges them to that opportunity.” That’s why these firms participate. Not for a 10% scalp. Not for a 2-day trade. They’re underwriting: future biotech optionality. And that is the first truly institutionally bullish signal QNCX has shown in a long time.

0 · Reply

Swihart_Art May. 19 at 3:20 PM

$QNCX 1.10 is a key level, if it breaks and holds then 1.20 pretty much guaranteed, it likes that level, and now the story has changed as of yesterday...

0 · Reply

Bossymc May. 19 at 3:18 PM

$QNCX lets gooooooo!

0 · Reply

Swihart_Art May. 19 at 3:16 PM

$QNCX already up 10% from my .98 entry... just saying, been doing this a while, just wait until it dips and you see strong buying, that's them, robbing retail, but also have MENTAL stops, don't show them on l2, they will hunt them, do your dd and you will prosper...

0 · Reply

_BUBBLES_ May. 19 at 3:15 PM

$QNCX Damn.. they really did straight up rob retail who sold under $1

0 · Reply

Papluch May. 19 at 3:11 PM

$QNCX ORTEX data is turning interesting SI ~12.7%, ⬆️ shares on loan 2.61M. ⬆️ utilization ~86%, ⬆️ CTB ~42%. ⬆️

0 · Reply

Market Cap	17.44M
Revenue (ttm)	0.00
Net Income (ttm)	-83.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,264,100
Avg Vol	6,205,466
Day's Range	N/A - N/A
Shares Out	16.30M
Stochastic %K	52%
Beta	1.45
Analysts	Hold
Price Target	$6.50